

RESULTS OF THE AGM 27 JUNE 2017

Paris, France and Cambridge, UK – 28 June 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, yesterday held its AGM. The results of the AGM are set out in the table below:

Resolutions	Votes For		Votes Against		Result
	Number	%	Number	%	
1) Approval of the parent company financial statements for 2016	8,856,982	100	0	0	Passed
2) Approval of the consolidated financial statements for 2016	8,856,982	100	0	0	Passed
3) Appropriation of profit for the year 2016	8,856,982	100	0	0	Passed
4) Review of the agreements referred to in Articles L. 225-38 et seq. of the French Commercial Code	8,740,279	98.68	116,703	1.32	Passed
5) Discharge to the Board of Directors	8,856,797	100	185	0	Passed
6) Authorisation to repurchase the Company's own shares	8,740,279	98.68	116,703	1.32	Passed
7) Renewal of the members of the Board of Directors	8,740,094	98.68	116,888	1.32	Passed
8) Appointment of Mr. Anthony Dyer as a member of the Board of Directors	8,013,820	90.48	843,162	9.52	Passed
9) Appointment of Ms. Juliet Thompson as a member of the Board of Directors	8,013,820	90.48	843,162	9.52	Passed
10) Determination of directors' attendance fees to be allocated to members of the Board of Directors	7,981,672	90.12	875,310	9.88	Passed
11) Modification of the statutes	8,740,279	98.68	116,703	1.32	Passed
12) Powers for formalities	8,856,982	100	0	0	Passed

Number of participating shareholders (by voting form, proxy or present): 59 shareholders representing 8,856,982 shares.

- End -

About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NovaPrep® and molecular platform, genesig® Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts

International

Brett Pollard / Victoria Foster Mitchell

FTI Consulting

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com

France

Arnaud de Cheffontaines / Astrid Villette

FTI Consulting

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

NOVACYT

Graham Mullis

Chief Executive Officer

+44 (0)7901 514 121

graham.mullis@novacyt.com